Medtronic plc (MDT)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Geoffrey Straub Martha
|
Chairman of the Board & CEO | 4.09M | 460.4k | 1970 |
|
Mr. Rogerio Branco
|
SVP & Chief Operations and Supply Chain Officer | -- | -- | -- |
|
Ms. Denise L. Blomquist
|
VP, Global Controller & Chief Accounting Officer | -- | -- | -- |
|
Dr. Laura Mauri M.D., M.Sc.
|
Senior VP and Chief Scientific & Medical Officer | -- | -- | 1970 |
|
Ms. Ingrid Goldberg
|
Vice President & Head of Investor Relations | -- | -- | -- |
|
Mr. Matthew R. Walter
|
Senior Vice President of Human Resources, IT and Global Communications & Corporate Marketing | -- | -- | 1979 |
|
Mr. Alex Gu
|
Senior VP & President of Greater China Region | -- | -- | -- |
|
Mr. Dave Anderson
|
Senior Vice President of Portfolio Management | -- | -- | -- |
|
Dave Moeller
|
Senior VP & President of the Peripheral Vascular Health Operating Unit | -- | -- | -- |
|
Ms. Sally Saba M.D.
|
Chief Inclusion & Diversity Officer | -- | -- | -- |
Medtronic plc
- Sector:
- Healthcare
- Industry: Medical Devices
- Full Time Employees:
- 95,000
Description
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Corporate Governance
Upcoming Events
November 17, 2026 at 12:30 PM UTC
Medtronic plc Earnings Date
Recent Events
October 16, 2026 at 12:00 AM UTC
Dividend Date
October 9, 2026 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
October 8, 2026 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
October 7, 2026 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
October 6, 2026 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
October 5, 2026 at 12:00 AM UTC
425: Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions
